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Monoamines are involved in regulating the endogenous pain system and indeed,
peripheral and central monoaminergic dysfunction has been demonstrated in certain
types of pain, particularly in neuropathic pain. Accordingly, drugs that modulate the
monaminergic system and that were originally designed to treat depression are now
considered to be first line treatments for certain types of neuropathic pain (e.g., serotonin
and noradrenaline (and also dopamine) reuptake inhibitors). The analgesia induced by
these drugs seems to be mediated by inhibiting the reuptake of these monoamines,
thereby reinforcing the descending inhibitory pain pathways. Hence, it is of particular
interest to study the monoaminergic mechanisms involved in the development and
maintenance of chronic pain. Other analgesic drugs may also be used in combination
with monoamines to facilitate descending pain inhibition (e.g., gabapentinoids and
opioids) and such combinations are often also used to alleviate certain types of
chronic pain. By contrast, while NSAIDs are thought to influence the monoaminergic
system, they just produce consistent analgesia in inflammatory pain. Thus, in this
review we will provide preclinical and clinical evidence of the role of monoamines in
the modulation of chronic pain, reviewing how this system is implicated in the analgesic
mechanism of action of antidepressants, gabapentinoids, atypical opioids, NSAIDs and
histaminergic drugs.
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INTRODUCTION
The monoaminergic system is implicated in the maintenance of homeostasis in the nervous system
and among their distinct functions, monoamines regulate the endogenous pain system (Bannister
et al., 2009). In terms of chronic pain, some recent contributions to the pharmacological arsenal of
analgesics that target monoamines are selective inhibitors of serotonin and noradrenaline reuptake
(SNRIs, e.g., duloxetine), and atypical opioids that combine their opioid activities with an effect
on monoamines (e.g., tramadol and tapentadol). These drugs have opened the way to consider
monoamines and their receptors as potential targets to develop innovative analgesics. Moreover,
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these drugs have also helped clarify the mechanism of action
of some so-called atypical analgesics, the primary effects of
which do not involve the monoaminergic system (i.e., tramadol,
tapentadol, nefopam) even though their global efficacy as
analgesics might well be driven by monoamines.
The most classic drugs that act directly on the monoaminergic
system are antidepressants, drugs that were not originally
designed as analgesics but that are currently considered first line
analgesics for some types of neuropathic pain (Finnerup et al.,
2005; Sindrup et al., 2005). Nevertheless, not all antidepressants
have analgesic properties. For years, amitriptyline has been
the most widely prescribed antidepressant but more recently,
the SNRI duloxetine has been positioned as an analgesic
antidepressant that can be used to treat peripheral diabetic
neuropathic pain and fibromyalgia. By contrast, selective
serotonin reuptake inhibitors (SSRIs) are not suitable analgesics
to treat neuropathic pain. Atypical opioid drugs combine an
opioid mechanism of action with another monoaminergic one,
producing effective analgesia in several types of chronic pain,
not only neuropathic pain (e.g., tramadol and tapentadol: Bravo
et al., 2017; Coluzzi et al., 2017). In this review, we will present
information from various preclinical and clinical studies that
investigated the role of monoamines in chronic pain, as well
as studies that assessed the mechanisms of action of actual and
potential analgesics to treat different types of chronic pain.
TYPES OF PAIN
Pain is necessary for our survival as it is a process that helps
protect us from danger and it serves as a short-term response
to resolve injury. However, pain that persists for longer than
3 months is considered to be a pathological state known as
chronic pain. Based on its etiology, pain is classified as: (i)
nociceptive, caused by lesion or potential tissue damage that
directly stimulates C and Aδ fibers (e.g., somatic and visceral
pain); (ii) inflammatory, caused by an inflammatory process
(e.g., arthritis); (iii) neuropathic, caused by a lesion or disease
affecting the somatosensory system (e.g., diabetic neuropathy,
post-herpetic and neuralgic sciatic nerve injury). These three
main types of pain can develop into chronic pain, although some
particular types of chronic pain may not be properly covered
by the categories of “nociceptive” or “neuropathic” pain, and
they can be categorized as “nociplastic pain.” This fourth type
of pain is characterized by altered nociception in the absence
of clear evidence of tissue damage or lesion, or of disease
that affects the somatosensory system (International Association
for Study of Pain, https://www.iasp-pain.org/PublicationsNews/
NewsDetail.aspx?ItemNumber=6862).
Regardless of its etiology, chronic pain is a public health
problem that affects 20% of the adult population in Europe
(Van Hecke et al., 2013). Chronic pain is one of the most
frequent reasons for visits to a physician and its estimated
financial cost exceeds €200 billion per annum in Europe and
$150 billion per annum in the United States (Tracey and
Bushnell, 2009). One of the main problems of chronic pain is its
inadequate management, most likely caused by ignorance of its
biological roots. The monoaminergic system can modulate pain
signaling and this system undergoes important alterations under
conditions of chronic pain, contributing to its persistance. In fact,
many types of chronic pain are now treated with medications
that affect monoamines and as such, these will be discussed
exhaustively in the present review.
PAIN MODULATION BY MONOAMINES
The monoaminergic system is an endogenous modulator of pain
(Bannister and Dickenson, 2016). Peripheral nociceptive signals
reach the spinal cord and the pain messages are relayed by
ascending projections targeting the thalamus, the dorsal reticular
nucleus (DRt), the rostral ventromedial medulla (RVM), and the
midbrain periaqueductal gray (PAG) which integrates forebrain
influences. The rostral projections from the thalamus target
areas that several sub-regions in the cortex and the amygdala
where both the sensory and affective components of pain are
processed. In parallel, descending monoaminergic pain pathways,
mainly from the Locus Coeruleus (LC) and RVM, modulate the
ascending nociceptive information at the level of the spinal cord.
These modulatory effects are mainly mediated by serotonin (5-
HT) and noradrenaline (NA), which may well represent potential
targets for new analgesic drugs (see below).
Noradrenergic Pain Modulation
The noradrenergic system is mainly implicated in descending
inhibitory pain with the noradrenergic descending projections
to the spinal cord mainly arising from the A6 (LC), A5 and A7
(Howorth et al., 2009). The effects of NA are mediated by the
α and β-NA adrenergic receptors, which are expressed widely in
the central and peripheral nervous systems (CNS and PNS), with
particularly strong expression in areas that directly participate in
pain processing (e.g., PAG, RVM, thalamus, LC, prefrontal cortex
and amygdala). There are various subtypes of adrenoceptors
(ARs), a- and β-ARs (α1A, α1B, α1D, α2A, α2B, and α2C; and
β1, β2, and β3: Ruffolo and Hieble, 1994), with the α2-ARs most
commonly associated with pain modulation. As we will describe
here, these receptors may be suitable pharmacological targets to
treat chronic pain.
Peripheral Noradrenergic Modulation
Noradrenaline is released locally by post-ganglionic sympathetic
nerve fibers (Pertovaara, 2006). Many α-ARs subtypes have been
identified in the dorsal root ganglia (DRGs: α1A, α1B, α1D,
α2A, and α2C) and also on the nerve fibers distributed to
the skin (Dawson et al., 2011) where peripheral nociception
is locally modulated (Shi et al., 2000; Xie et al., 2001; Maruo
et al., 2006). Although α2-AR agonists mainly produce analgesia
via spinal and supraspinal action (Bernard et al., 1994; Buerkle
and Yaksh, 1998; Asano et al., 2000), peripheral ARs also
fulfill an important role in analgesia (Pertovaara, 2006). Thus,
topical α2 agonist administration produces analgesia, an effect
that is blocked by pretreatment with AR antagonists in acute
and chronic pain rat models (Nakamura and Ferreira, 1988;
Dogrul and Uzbay, 2004). Accordingly, topic administration of
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clonidine relieves hyperalgesia in patients with complex regional
pain syndrome (Davis et al., 1991), indicating that peripheral
stimulation of α2-ARs could relieve neuropathic pain. β2-ARs
are located on peripheral terminals and cell bodies of primary
afferent nociceptors (Aley et al., 2001). Nevertheless, it remains
unclear if activation of β2-ARs is pro- or anti-nociceptive. Most
preclinical studies have shown that peripheral β2-AR stimulation
by antidepressants induces anti-allodynic effects in neuropathic
pain models (Bohren et al., 2013; Kremer et al., 2018), while
intradermal injection of epinephrine produces hypersensitivity
(Khasar et al., 1999; Parada et al., 2003).
Central Noradrenergic Modulation
Preclinical studies reported that chemical or electrical
stimulation of the LC, the main noradrenergic nucleus,
induces analgesia via the spinal cord that is blocked by spinal
α2-AR antagonists (Pertovaara, 2006). The LC sends projections
to all cortical regions, as well as to the basolateral amygdala
(BLA), hippocampus, and ventral tegmental area (VTA), all of
which express adrenergic receptors and are relevant structures
in the context of pain (Loughlin et al., 1986; Sara and Bouret,
2012). Moreover, the LC express a large proportion of the α2-AR
inhibitory auto-receptors that modulate NA release via these
projections (Llorca-Torralba et al., 2016). Despite the prevalence
of studies focusing on the LC in pain modulation, there is also
evidence that other noradrenergic nuclei play a role in pain
processing (Llorca-Torralba et al., 2016). Indeed, the A5 and A7
noradrenergic clusters provide significant NA input to the spinal
cord, where the final balance between inhibitory and facilitatory
modulation of pain takes place (Pertovaara, 2006; Bruinstroop
et al., 2012). These findings provide evidence of the complex
interaction between NA and pain. At present, the role of NA
on spinal adrenergic receptors seems to be clearer than that its
effects on supraspinal noradrenergic receptors.
Serotonergic Pain Modulation
Serotonin (5-HT, 5-hydroxytryptamine) has been widely related
to pain modulation through peripheral and central actions.
Unlike NA, which action seem to be more related to analgesia, 5-
HT acts on specific receptors that contribute to the maintenance
of pain (Suzuki et al., 2004; Bannister and Dickenson, 2016).
Peripheral Serotonergic Modulation
Serotonergic nociceptive transmission at peripheral sensory
nerves is mediated by several subtypes of 5-HT receptors (5-
HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT3, 5-HT4, and 5-HT7)
known to exist in DRGs (Pierce et al., 1996; Wu et al., 2001).
Numerous studies have shown that peripheral administration of
5-HT increases the excitability of Aδ and C fibers, and DRG
neurons (Michaelis and Janig, 1998; Lang et al., 2006), suggesting
a pro-nociceptive role for 5-HT. Indeed, intradermal injection of
5-HT in rats produces dose-dependent hypersensitivity mediated
by 5-HT1A receptors (Taiwo et al., 1992). Moreover, peripheral
injection of 5-HT2A, 5-HT3, and 5-HT7 antagonists produces
an anti-nociceptive effect in a model of the formalin pain test
(Rocha-González et al., 2005; Nakajima et al., 2009; Godinez-
Chaparro et al., 2011). In clinical studies on healthy volunteers,
intradermal injection of 5-HT produces burning pain (Lischetzki
et al., 2001) and the hypersensitivity induced by 5-HT injections
into the masseter muscle is antagonized by a 5-HT3 antagonist
(Ernberg et al., 2000).
Central Serotonergic Modulation
Descending serotonergic pathways include the RVM, where
the midline raphe magnus nucleus (RMN) can inhibit or
facilitate descending pain (Fields, 2004). ON and OFF cells,
respectively, in the RVM send descending inhibitory and
excitatory fibers to the dorsal horn spinal cord neurons that
control the spinal sensory transmission (Urban and Gebhart,
1999; Neubert et al., 2004). Thus, activation of the RVM by
electrical stimulation or glutamate microinjection evokes the
spinal release of 5-HT, inducing analgesia (Oliveras et al., 1975;
Satoh et al., 1983; Aimone and Gebhart, 1986). The RVM
receives projections from the periaqueductal gray (PAG) and the
microinjection of opioids in RVM has an inhibitory effect on
noxious stimulation, indirectly activating OFF cells and thereby
reducing pain (Zorman et al., 1981; Jensen and Yaksh, 1989;
Heinricher et al., 1994).
It was largely demonstrated that the effect of spinal 5-
HT is either inhibitory or facilitatory, depending on the 5-
HT receptor subtypes activated (Green et al., 2000; Millan,
2002; Dogrul and Uzbay, 2004; Suzuki et al., 2004). In pain
modulation, 5-HT exerts excitatory effects via the 5-HT2 and 5-
HT3 receptors, yet an inhibitory effect is provoked by stimulation
of 5-HT7 receptors (Obata et al., 2001; Viguier et al., 2013;
Bannister et al., 2017). However, the 5-HT1A receptor could
exert excitatory or inhibitory effects (Millan, 2002). Except to
treat chronic migraine, no drugs targeting 5-HT receptors are
used for chronic pain. Thus, central action of 5-HT clearly needs
further investigation in order to understand how 5-HT modulates
pain, and its implication as a possible analgesic agent in acute
and chronic pain.
Dopaminergic Pain Modulation
The role of dopamine (DA) in pain modulation has received less
attention than that of NA and 5-HT. The dopaminergic system
is widely known to participate in mesocorticolimbic reward
system, which arises from the VTA and modulates emotion-
related behavior (Baik, 2013). Interestingly, dopamine plays a role
in the modulation of nociceptive transmission at both the spinal
and supraspinal levels (Potvin et al., 2009). In the CNS, there
are five subtypes of DA receptors (D1-D5), and the D1 and D2
receptors are those most strongly implicated in pain modulation,
as witnessed in animal models (Millan, 2002). As such, activation
of D2 receptors at the spinal level induces an anti-nociceptive
effect (Magnusson and Fisher, 2000; Taylor et al., 2003; Ansah
et al., 2007; Coffeen et al., 2008; Meyer et al., 2009), whereas
stimulation of D1 receptors is pro-nociceptive (Gao et al., 2001;
Yang et al., 2005; Kim et al., 2015).
Focal electrical stimulation of descending dopaminergic
projections suppresses painful transmission at the spinal cord
level, mainly through the A11 nucleus of the pericentral posterior
hypothalamus and substantia nigra (Fleetwood-Walker et al.,
1988). Thus, both acute and sustained noxious stimuli increase
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DA release to D2 receptors of spinothalamic and primary
nociceptive neurons, eliciting an anti-nociceptive response
(Millan, 2002). D1 receptor activation in the PAG or insular
cortex has also been seen to attenuate pain-related behavior,
presumably through the activation of neurons involved in
descending inhibition (Burkey et al., 1999; Flores et al., 2004). The
spinal effect of DA appears to depend on its local concentration.
Low levels of DA may activate the anti-nociceptive D2 receptors,
whereas higher levels would activate the pro-nociceptive D1
receptors (Paulus and Trenkwalder, 2006).
Interestingly, there appears to be an interaction between the
noradrenaline transporter (NAT) and DA release in areas like
the VTA, LC and dorsal hippocampus (Moron et al., 2002;
Carboni and Silvagni, 2004; Guiard et al., 2008). Similarly, a
small population of DA-synthesizing cells exists in DRGs (Millan,
2002) and consequently, it is possible that noradrenergic neurons
constitute an important source of DA in the dorsal horn to
control pain. Moreover, there is also an interaction between
the DA and opioid system, and significantly, dopaminergic
neurons are necessary for the anti-nociceptive effect of morphine,
particularly in the PAG (Flores et al., 2004; Meyer et al., 2009).
These findings suggest that dopaminergic pathways and their
regulation by noradrenergic inputs fulfill an important role
in the control of nociceptive transmission. In this context,
antidepressants that act on the dopaminergic system might
represent new therapeutic tools in the treatment of chronic pain,
such as bupropion or more recently, triple reuptake inhibitors
(TRIs: Xie et al., 2001; Hache et al., 2011; Navratilova et al., 2012).
Histamine in Pain Modulation
Histamine 2-(4-Imidazolyl)ethylamine) is released from
neuronal and non-neuronal sources and it is a mediator of
many physiological processes, including the modulation of
pain. Histamine is released peripherally in response to tissue
injury that directly sensitizes nociceptors and it contributes
to the generation of pain hypersensitivity (Kajihara et al.,
2010). By contrast, the role of histamine in the CNS remains
unclear. Preclinical studies have shown that histamine injected
directly into supraspinal areas (e.g., the somatosensory cortex
or hippocampus) attenuates pain (Erfanparast et al., 2010;
Tamaddonfard and Hamzeh-Gooshchi, 2014), while intrathecal
injection of histamine appears to facilitate nociception (Yoshida
et al., 2005). Histamine interacts with four receptor subtypes
(H1, H2, H3 and H4), which are expressed in both presynaptic
and post-synaptic neurons (Brown et al., 2001). H1 and H2
are excitatory receptors mainly located postsynaptically (Brown
et al., 2001; Zhang et al., 2013), and systemic inhibition of
these receptors has antinociceptive effects in rats when assessed
with the formalin test (Mojtahedin, 2016). H3 receptors are
predominantly expressed in the central and peripheral nervous
system (Panula et al., 2015). This receptor is mainly localized
presynaptically in histaminergic neurons with inhibitory
activity that regulate the levels of histamine (Hough and Rice,
2011), while its post-synaptic localization in non-histaminergic
neurons regulates the release of neurotransmitters, such as ACh,
dopamine, 5-HT and noradrenaline (Obara et al., 2019). H4
receptors possess inhibitory activity and they are expressed
in neurons, although their location in the nervous system
remains uncertain (Connelly et al., 2009). Thus, histamine
exerts different effects on pain modulation depending on the
receptor subtype with which it interacts and no histaminergic




Chronic pain induces monoaminergic plasticity at peripheral and
central areas which lead to the classical signs of persistent pain
(Figure 1 and Table 1; Hains et al., 2002; Sounvoravong et al.,
2004; Heinricher et al., 2009; Morgado et al., 2011; Alba-Delgado
et al., 2013). Thus, a review of the monoaminergic dysfunction in
chronic pain may identify potential drug targets.
Noradrenaline
Peripheral α-adrenergic stimulation does not affect pain
sensation in healthy conditions but interestingly, such excitation
enhances pain sensation in chronic pain (Shea and Perl, 1985).
This pro-nociceptive effect is the result of increased excitability
of primary sensory neurons, known as hypersensitivity to
innocuous and noxious stimuli. The increase in excitability
is the result, in part, of neuroplastic changes in animal
models of chronic pain, driven possibly by an increase in
α2- and α1B-AR mRNA expression in DRGs (Sato and Perl,
1991; McLachlan et al., 1993; Bossut and Perl, 1995; Xie
et al., 2001; Maruo et al., 2006) and by upregulation of α1-
ARs on cutaneous nociceptive afferents (Drummond et al.,
2014). Interestingly, this excitability is enhanced by α2 agonists
while it is blocked by administration of α2 antagonists (Sato
and Perl, 1991; McLachlan et al., 1993). Based on these
studies, it was proposed that the effect of the increase in α2-
AR expression on afferents contributes to the maintenance
of chronic pain, making this a potential target to relieve
peripheral chronic pain.
Spinal α-ARs are thought to play an opposite role to
peripheral ARs in chronic pain. An increase in spinal α2A-
ARs has been reported in sheep with inflammatory pain
(Brandt and Livingston, 1990), while in rats, neuropathic
pain has been associated with an increase in spinal α2C-
ARs but not α2A-ARs (Stone et al., 1999). Similarly, the
number of spinal α2A-ARs in spinal nerve ligation (SNL)
rats remains unaltered but surprisingly, an increase in the
efficacy of coupling between α2A and Gα subunits has
been reported (Bantel et al., 2005). Additionally, upregulation
of the spinal NAT has been reported in such SNL rats
(Rojo et al., 2012). These results suggest that chronic pain
induces adaptive changes in response to reduced descending
noradrenergic tone (Hughes et al., 2013). Interestingly, the
increase in α2A-AR efficiency could explain why antidepressants
induce spinal analgesia in chronic pain conditions (Luo
et al., 1994; Malmberg et al., 2001; Bantel et al., 2005).
These central adaptive changes suggest that after nerve
injury, the descending noradrenergic inhibitory tone may be
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FIGURE 1 | Peripheral and central adaptive changes observed in animal models of chronic pain. DRG, dorsal root ganglion; DRN, dorsal raphe nucleus; RMN, raphe
magnus nucleus; vlPAG, ventrolateral periaqueductal gray; DBH, dopamaine beta-hydroxylase; TH, tyrosine hydroxylase; NAT, noradrenaline transporter.
compromised but interestingly, the increase in the α2-AR
efficacy can be considered beneficial for the effect of NA
reuptake inhibitors.
Although spinal adrenergic alterations have received special
attention in the development of chronic pain, supraspinal
noradrenergic areas have also been seen to change in a
manner that is relevant to chronic pain. Thus, an increase
in dopamine beta-hydroxylase (DBH), tyrosine hydroxylase
(TH), NAT and α2-ARs has been observed in the LC of
rats with long-term neuropathic pain (Alba-Delgado et al.,
2013; Tazawa et al., 2015). All these changes might try to
balance the reduced spinal noradrenergic tone observed in
neuropathic pain, although in recent decades these alterations
have been seen to be relevant for the development of
secondary co-morbidities in chronic pain, such as anxiety
and depression (Alba-Delgado et al., 2013, 2018). It has also
recently been demonstrated that neuropathic pain induces
LC-BLA overactivation, leading to anxiety-like behaviors, and
enhancing the aversive learning and memory index (Llorca-
Torralba et al., 2019). In addition, optogenetic activation of the
LC-PFC (prefrontal cortex) pathway exacerbates spontaneous
pain, producing aversion and increasing anxiety-like behavior
(Hirschberg et al., 2017). Interestingly, other noradrenergic
nuclei (A5 and A7) contribute to the maintenance of chronic
pain. Thus, the A7 seems to exert an inhibitory effect on LC
neurons in neuropathic pain (Wei and Pertovaara, 2013), while
the A5 nucleus sends projections to the dorsal reticular nucleus
(DRt) that contributes to the facilitation of pain transmission
in the spinal cord via α1-ARs (Lima and Almeida, 2002;
Martins et al., 2015).
Serotonin
The serotonergic descending pain pathways also experiences
alterations in animal models of chronic pain. The effect of
spinal 5-HT may be either inhibitory or facilitatory, depending
on the acute or chronic state of pain (Millan, 2002). Thus,
intrathecal administration of 5-HT produces anti-nociception
against acute stimuli of diverse nature (Crisp et al., 1991; Bardin
et al., 1997), whereas the depletion of 5-HT pathways in models
of neuropathic (chronic) pain prevents hypersensitivity (Suzuki
et al., 2004; Rahman et al., 2006). Interestingly, reduced spinal
5-HT levels in mice deficient for the 5-HT transporter (5-
HTT−/−) is associated with decreased thermal hypersensitivity, a
symptom caused by peripheral sensitization in pain (Vogel et al.,
2003). Thus, it has been suggested that 5-HT might facilitate
persistent pain while it has also been proposed that 5-HT could
be inhibitory in neuropathic pain.
Regarding 5-HT receptor stimulation, 5-HT1As have been
implicated in both facilitatory (i.e., pronociception; Alhaider
and Wilcox, 1993) and inhibitory pain (i.e., anti-nociception;
Bardin et al., 2001). The activation of 5-HT1A autoreceptors
at the supraspinal levels regulates 5-HT release to the spinal
cord and therefore, acute 5-HT1A agonist administration
dampens 5-HT release in the spinal cord (Sprouse and
Aghajanian, 1987). In animal models of neuropathic pain,
the antagonism of 5-HT1A receptors induces analgesia or
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TABLE 1 | Monoaminergic dysfunction in preclinical models of pain.
System Finding reported Model of pain Animal References
Noradrenergic
Peripheral ↑ α2-AR Sciatic nerve ligation Rat McLachlan et al., 1993
(DRG) ↑ α1B-AR SNL, Sciatic nerve ligation Rat Xie et al., 2001; Maruo et al., 2006
↓ Kv channel alpha CCI Rat Kim et al., 2001, 2002
Spinal ↑ α2A-AR Inflammatory pain Sheep Brandt and Livingston, 1990
↑ α2C-AR SNL Rat Stone et al., 1999
↑ Efficacy of coupling between α-2AR and Gα SNL Rat Bantel et al., 2005
↑ NAT SNL Rat Rojo et al., 2012
Supraspinal ↑ TH
(locus coeruleus) ↑ NAT CCI Rat Alba-Delgado et al., 2013
↑ α2-AR
↑ DBH SNL Rat Tazawa et al., 2015
Serotonergic
Peripheral ↑ 5-HT2A in DRG Vincristine-induced neuropathy Rat Thibault et al., 2008
Spinal ↑ 5-HT2A in ipsilateral side of dorsal horn CFA Rat Zhang et al., 2001, 2002
↑ 5-HT2A in the lumbar dorsal horn Vincristine-induced neuropathy Rat Thibault et al., 2008
↓ 5-HT7 in dorsal spinal cord Formalin test Rat Rocha-González et al., 2005
↓ 5-HT7 in ipsilateral dorsal spinal cord SNL Rat Amaya-Castellanos et al., 2011
Supraspinal ↑ 5-HT2A bilateral NRM CFA Rat
↑ 5-HT2A vlPAG CFA Rat Zhang et al., 2001, 2002
↑ 5-HT2A DRN CFA Rat
Dopaminergic
Supraspinal ↓ D2 receptor in the NAc SNI Rat Sagheddu et al., 2015
Disruption on D2 and D3 receptors in the hippocampus SNI Rat Cardoso-Cruz et al., 2014
Histaminergic
Peripheral ↑ H1 receptor in nociceptive afferent neurons Capsaicin-induced hyperalgesia Guinea pig Kashiba et al., 2001
AR, adrenoceptor; CCI, chronic constriction injury; CFA, complete Freund’s adjuvant; DBH, dopamine beta hydroxylase; DRG, dorsal root ganglion; DRN, dorsal raphe
nucleus; NAc: accumbens nucleus; NAT, noradrenaline transporter; NRM: raphe magnus; SNI, spared nerve injury; SNL, spinal nerve ligation; TH, tyrosine hydroxylase;
vlPAG, ventrolateral periaqueductal gray.
it potentiates the effect of morphine, tramadol and anti-
depressants (Rojas-Corrales et al., 2000, 2005; Ardid et al.,
2001; Anjaneyulu and Chopra, 2004), suggesting a facilitatory
role for this receptor in neuropathic pain at least. By
contrast, chronic administration of the 5-HT1A agonist F-
13640 induced analgesia in an animal model of constriction
injury of the infraorbital nerve (Colpaert, 2006; Colpaert et al.,
2006). This response could be due to the desensitization of
autoreceptors in supraspinal areas following chronic 5-HT1A
administration. Therefore, the pro-nociceptive effects of 5-
HT1A agonist administration have been attributed to pre-
synaptic 5-HT1A, while anti-nociceptive effects could be due
to the post-synaptic 5-HT1A activation at the spinal level
(Colpaert, 2006).
Antagonism of 5-HT2 and 5-HT3 receptors is thought to
dampen analgesia or potentiate the effect of some drugs due to
its role in descending facilitation pain (Ali et al., 1996; Green
et al., 2000). Interestingly, there are increases in the prominence
of these receptors in association with chronic pain. Thus, an
increase of 5-HT2A receptor mRNA was evident in DRGs, the
RMN, ventrolateral PAG (vlPAG), dorsal raphe nucleus (DRN)
and dorsal horn in a model of inflammatory pain (Zhang et al.,
2001, 2002). Similarly, an increase in the 5-HT2A receptor has
been reported in the lumbar dorsal horn in association with
neuropathic pain (Thibault et al., 2008). Clinical studies reported
an increase in 5-HT2A receptor binding in the PFC related
to the pain evoked by heat (Kupers et al., 2009), suggesting
a clear facilitation role for this receptor. As such, antagonism
of this receptor could be a potential target for the treatment
of chronic pain.
Although 5-HT3 receptor expression remains unaltered in
the dorsal spinal horn in neuropathic pain (Peters et al., 2010),
antagonism of the 5-HT3 receptor reduces the second but not the
first phase of the formalin test, suggesting that the agonism of the
5-HT3 receptor would facilitate chronic pain (Glaum et al., 1988,
1990; Green et al., 2000). In addition, an increase in serotonergic
fibers (5 weeks after spinal cord injury -SCI) was proposed to
contribute to the maintenance of mechanical allodynia via 5-HT3
receptor activation (Oatway et al., 2004). These findings suggest
that 5-HT3 and 5-HT2A receptors that participate in facilitatory
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descending pain contribute to the central sensitization in chronic
pain conditions (Bannister and Dickenson, 2017).
There is little information available from a clinical setting,
although a decrease in mechanical allodynia was observed
in some patients with neuropathic pain treated with a 5-
HT3 receptor antagonist (McCleane et al., 2003) but not
in others (Tuveson et al., 2011). Although selective 5-HT3
receptor antagonists (used as anti-emetics) have inflammatory
and analgesic properties in patients suffering inflammatory
rheumatic diseases and fibromyalgia (Stratz and Muller, 2000;
Vergne-Salle et al., 2011), there are no clinically effective drugs
that act on these receptors.
The 5-HT7 receptor has been little studied in chronic pain.
While it is thought to be less prominent in the dorsal spinal
cord of neuropathic rats, its antagonism seems to produce
analgesic properties in neuropathic and inflammatory pain
models (Rocha-González et al., 2005; Amaya-Castellanos et al.,
2011; Bannister and Dickenson, 2017).
Thus, it is difficult to elucidate the role of 5-HT and its
receptors in pain because such effects are highly dependent on the
5-HT receptor subtype stimulated but also, on the pathological
state of the subject.
Dopamine
Interest in the role of the dopaminergic system in pain
has augmented in the last decade. Some changes in the
mesocorticolimbic circuit have been reported, considered as a
possible target to combat the negative affective states associated
with chronic pain. A decrease in D2 receptor expression has
been reported in the nucleus accumbens (NAc) of animal models
of neuropathic pain, as well as changes in D2 and D3 receptor
expression in the hippocampus (Cardoso-Cruz et al., 2014;
Sagheddu et al., 2015). In addition, a reorganization of NAc
connectivity with cortical areas contralateral (to the injured limb)
has been reported in a model of long-term neuropathic pain
(Chang et al., 2014). The dopaminergic alterations studied seem
to contribute to the negative motivational-affective (Taylor et al.,
2003; Scott et al., 2006; Chang et al., 2014) and cognitive aspects
of pain (Cardoso-Cruz et al., 2014).
Histamine
The histaminergic system seems play an important role in the
development of hypersensitivity in neuropathic pain (Obara
et al., 2019). Histamine is released peripherally by mast cells
that are involved in the inflammatory process through the
recruitment of macrophages and neutrophils following nerve
injury (Calvo and Bennett, 2012). In fact, mast cell depletion
prevents mechanical hypersensitivity in a mouse model of
persistent pain (Kaur et al., 2017). These mast cells proliferate
and can degranulate for up to 2 weeks or even for months under
certain conditions of nerve injury (Hayashi et al., 2008). In terms
of the histamine receptors, an increase in H1 receptor expression
has been observed in nociceptive afferent neurons after nerve
injury (Baron et al., 2001; Kashiba et al., 2001) and interestingly,
histamine seems to activate the pruriceptors that induce the
release of inflammatory mediators involved in pruritus (itching:
Parsons and Ganellin, 2006). There is also evidence indicating
that histamine-induced itching can convert into pain associated
with neuropathic hypersensitivity (Baron et al., 2001). Thus, the
histaminergic system may be subject to alterations that contribute




The analgesic activity of antidepressants has been widely
demonstrated in animals and humans. Although antidepressants
can be used to alleviate certain types of chronic pain, mainly
neuropathies, their mechanism of action as analgesics remain
unclear (Obata, 2017). Given the central role of monoamines in
pain modulation it is highly likely that antidepressants exert some
effect on pain circuits. The hypotheses regarding the analgesic
activity of these drugs focuses on their ability to augment the
presence of monoamines by inhibiting NA and 5-HT reuptake.
Antidepressants block NA and 5-HT transporters, preventing
presynaptic reuptake and thereby increasing the post-synaptic
NA and/or 5-HT that reinforces descending pain inhibitory
pathways (Hache et al., 2011; Obata, 2017). However, other
actions on the monoaminergic system have also been described
for these drugs, as described below (Table 2).
Action on the Noradrenergic System
Preclinical Studies
Animal studies suggest that α2-ARs are involved in the analgesia
mediated by antidepressants (Ghelardini et al., 2000; Hajhashemi
et al., 2014), the most relevant evidence provided by the
loss of analgesia induced by amitriptyline in α2-AR KO mice
(Ozdogan et al., 2004). In addition to α2-ARs, other adrenergic
receptors have also been implicated in the analgesia mediated by
antidepressants. Thus, the α1-AR antagonist prazosin blocked the
anti-nociceptive effect of nortriptyline, maprotiline, milnacipran,
and imipramine in the formalin test (Yokogawa et al., 2002).
In terms of β-ARs, initial studies reported that β1- and β2-ARs
participated in the analgesia mediated by desipramine (DMI)
and nortriptyline, in both thermal and chemical models of
acute pain (Mico et al., 1997). Interestingly, in neuropathic
mice lacking β2-ARs chronic treatment with DMI, nortriptyline
and reboxetine failed to produce analgesia (Yalcin et al., 2009),
consistent with preclinical findings where repeated stimulation
of β2-ARs seem to be necessary and sufficient to produce a
therapeutic effect (Choucair-Jaafar et al., 2009, 2011; Yalcin
et al., 2009, 2010). More recently, mianserin, a tetracyclic
antidepressant, was shown to produce analgesia in a model of
diabetic neuropathic pain through its interactions with both
α2- and β-ARs (Ücel et al., 2015). In addition, antidepressants
may possibly have peripheral effects, with nortriptyline and
venlafaxine mediating the stimulation of β2-ARs in non-neuronal
cells, thereby inhibiting the production of the cytokine tumor
necrosis factor α (TNFα), provoking an anti-allodynic effect in
a rat model of neuropathic pain (Bohren et al., 2013).
All the data available suggest that the analgesic action
of antidepressants mainly occurs at the spinal level





















TABLE 2 | Antidepressants with analgesic action via monoaminergic system.




Acute pain Amitriptyline 15 mg/Kg i.p. Hot plate ↑ Latency α2-AR Reserpine (2 mg/kg
i.p.)








(+) Oxaprotiline 10, 35 mg/kg i.p. Abdominal
constriction
Acetic acid test ↓ No constriction α2-AR RX821002
(1 mg/kg s.c.)
Mice Gray et al., 1999
Paroxetine 10 mg/kg i.p.
Sibutramine 5, 25 mg/kg i.p.
Dothiepine 5, 30 mg/kg i.p.
Amitriptyline 5, 25 mg/kg i.p.
TCA: Amitriptyline 10 mg/kg i.p. Heat stimulation Tail-flick test Not displays
analgesic effect
α2-AR α2-AR KO Mice Ozdogan et al.,
2004
Desipramine 4, 20, 40 mg/kg
i.p.
Hot plate test ↑ Latency β1-AR CGP20712A
(1 mg/kg s.c.)
Mice Mico et al., 1997
Nortriptyline 2, 4, 20,
40 mg/kg i.p.




Acetic acid test ↓ No constriction
Inflammatory Formalin test (first
phase)
↓ licking time
Chronic pain Venlafaxine 40 mg/kg i.p. Neuropathic: CCI Plantar test ↑ Latency α2-AR Yohimbine
(5 mg/kg i.p.)
Rat Hajhashemi et al.,
2014
10, 20 mg/kg i.p.
(14 days)
von Frey test ↑ Withdrawal
threshold
SNRI: Duloxetine 10 mg/kg s.c.
(3 days)
Neuropathic: SNL von Frey test ↑ Withdrawal
threshold
α2-AR Idazoxan
(30 µg/20 µg i.t.)
Rat Ito et al., 2018
Nortriptyline,
Imipramine
5 mg/kg i.p. Inflammatory Formalin test (late
phase)
↓ Licking time α1-AR Prazosin (1 mg/kg
i.p.; 5 µg, i.c.v.)
Rat Yokogawa et al.,
2002
Nisoxetine 2.5 mg/kg i.p.
Maprotiline 10 mg/kg i.p.
Milnacipran 5 mg/kg i.p.
Fluvoxamine 20 mg/kg i.p.
Mianserin 30, 45 mg/kg
o.p. (14 days)





Rat Ücel et al., 2015





Plantar test ↑ Latency









































TABLE 2 | Continued
Drugs Effective Dose Model of pain Nociceptive test Effect Receptors Effect
antagonized by
Animal References
Nortriptyline 5 mg/kg i.p.
(2–3 weeks)






Desipramine 5 mg/kg i.p.
(4 weeks)





β2-AR +/+ Mice Yalcin et al., 2009




Reboxetine 0.8 mg/kg i.p.
(4 weeks)
Nortriptyline 5 mg/kg i.p.
(2–3 weeks)

















Acetic acid test ↓ No constriction 5-HT1A Pindolol (10 mg/kg
i.p.)
Mice Singh et al., 2001
Fluoxetine 0.3–1 nmol/paw Inflammatory Formalin test (first
phase)
↑ Fliching Rat Cervantes-Durán
et al., 2013




Acetic acid test ↓ No constriction 5-HT3 Ondansetron
(0.1 mg/kg)
Mice Kesim et al., 2005
Fluvoxamine 30 mg/kg i.p. Paw pressure test ↑ Latency 5-HT3 Granisetron
(1 mg/kg, s.c)
Mice Honda et al., 2006









Mice Honda et al., 2006
Fluoxetine 0.3–1 nmol/paw Formalin test (late
phase)




























































TABLE 2 | Continued
Drugs Effective Dose Model of pain Nociceptive test Effect Receptors Effect
antagonized by
Animal References
5-HT1B/1D GR-127935 (1 nmol i.t.)
HT1B SB-224289 (1 nmol i.t.)
5-HT1D BRL-15572 (1 nmol i.t.)
Imipramine 10 mg/kg i.p. Inflammatory Formalin test (late
phase)
↓ Licking time 5-HT3 Ondansetron (1 mg/kg
i.p.)
Rat Yokogawa et al.,
2002
Nortriptyline 5, 10 mg/kg i.p. 5-HT2 Ketanserin (1, 2 mg/kg
i.p; 60 µg i.c.v.)
Nisoxetine 2.5 mg/kg i.p.
Maprotiline 10 mg/kg i.p.
Milnacipran 5 mg/kg i.p.
Fluvoxamine 20 mg/kg i.p.
Imipramine 2.5 mg/kg i.p. Formalin test (late
phase)
↑ Licking time 5-HT4 SDZ-205, 557
(0.1 mg/kg i.p.)
Fluoxetine 10 mg/kg i.p.
(3 weeks)




Rat Pichon et al., 2010
Hot plate ↑ Latency




Hot-plate test ↑ Latency




5-HT1A WAY 100, 635 (0.5,
8 mg/kg s.c.)
Rat Ardid et al., 2001
Venlafaxine 5, 10, 20 mg/kg
i.v.
Neuropathic: CCI Randall-Selitto ↑ Vocalization
thresholds
5-HT1A OH-DPAT (0.5 mg/kg
s.c.)






Acute pain Nomifensine 1.25, 2.5, 5,
10 mg/kg s.c






Hot plate Not displays
analgesic effect
Formalin test ↓ Licking time
Chronic pain Amitriptyline 3–30 mg/kg i.p. Neuropathic: SNL von Frey test ↑ Withdrawal
threshold




AR, adrenoceptor; CCI, chronic constriction injury; i.p., intraperitoneal injection; i.v, intravenous injection; i.t. intrathecal injection; s.c., subcutaneous injection; SNC: sciatic nerve cuffing; SNL, spinal nerve ligation; STZ,
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(Mico et al., 2006; Ito et al., 2018; Kremer et al., 2018). Indeed,
it was recently verified that daily subcutaneous injections of
duloxetine attenuate SNL hypersensitivity in rats through NA
accumulation in the spinal cord (Ito et al., 2018). Given the role
of the LC in analgesia through the descending pain pathway,
the effect of antidepressants at this level has been evaluated.
As expected, electrophysiological assays have demonstrated the
action of antidepressants on the LC neurons, for example the
acute administration of venlafaxine (a SNRI) completely inhibits
the LC activity modulated by α2-ARs and 5-HT1A receptors
(Berrocoso and Mico, 2007). Interestingly, DMI and duloxetine
restored the functional changes in rat LC neurons affected
by neuropathic pain, an event that correlated with analgesic
behavior (Alba-Delgado et al., 2012). Similarly, functional
Magnetic Resonance Imaging (fMRI) showed that chronic
administration of DMI (14 days, daily i.p. of 10 mg/kg) produced
greater activation of areas altered by chronic pain in a rat model
of neuropathic pain: primary somatosensory cortex, insular
cortex, medial globus pallidus, etc. (Jones et al., 2009).
Clinical Approach
Antidepressants that mainly inhibit noradrenaline reuptake, like
DMI and maprotiline, are not a good choice for the treatment
of human neuropathic pain (Max et al., 1991, 1992; Vrethem
et al., 1997), yet they are used in patients who have not obtained
pain relief with other treatments. Clinical evidence suggests
that dual antidepressants provide better analgesic efficacy in
chronic neuropathic pain. In this regard, the analgesic efficacy
of amitriptyline (a tricyclic antidepressant -TCA) is the best-
documented in complex regional pain syndrome, neuropathic
and musculoskeletal pain, and fibromyalgia (Wiffen et al., 2013;
Moore et al., 2015; Brown et al., 2016; van den Driest et al.,
2017). However, due to the side effects of TCAs, the SNRI
duloxetine has been the first choice treatment for peripheral
diabetic neuropathic pain and fibromyalgia, with a good safety
profile. Despite the efficacy revealed in these conditions, this
class of antidepressants is not useful in relieving SCI, phantom
limb and HIV neuropathy (Kieburtz et al., 1998; Cardenas et al.,
2002; Robinson et al., 2004), yet there is insufficient evidence to
prescribe antidepressants for inflammatory chronic pain (Perrot
et al., 2006; Richards et al., 2011). Thus, more clinical trials are
needed in this area.
Regarding the mechanisms of action, it is believed that the
increase of monoamines associated with the inhibition of NA and
5-HT reuptake reinforces inhibitory descending pain pathways
(Obata, 2017). Clinical studies have reported the importance
of stimulating α2A-AR to induce analgesia and indeed, α2
agonist administration has anti-nociceptive activity alone or in
combination with opioids (Eisenach et al., 1994, 1995). In clinical
practice, antidepressants exhibit little or only intermediate
efficacy against acute nociceptive stimuli, while they induce
significant analgesia in chronic pain (Poree et al., 1998; Sawynok
et al., 2001; Paqueron et al., 2003; Mico et al., 2006). Interestingly,
enhanced α2A-AR efficiency could explain why antidepressants
induce spinal analgesia in chronic pain (Luo et al., 1994;
Malmberg et al., 2001; Bantel et al., 2005). Accordingly, drugs
acting through α2-ARs such as clonidine is effective in patients
with neuropathic pain at doses that are inactive in post-operative
pain (Eisenach et al., 1995). Although preclinical evidence
indicates that β2-ARs are necessary to produce a therapeutic
effect (Choucair-Jaafar et al., 2009, 2011; Yalcin et al., 2009, 2010),
there is one clinical report supporting the efficacy of β2-ARs in
combating neuropathic pain (Cok et al., 2010).
Action on the Serotonergic System
Preclinical Studies
Like noradrenaline, the main putative analgesic mechanism
for 5-HT is the increase of 5-HT neurotransmission by 5-HT
receptor stimulation and the ensuing modulation of descending
pain inhibition. However, specific 5-HT receptor subtypes can
dampen or enhance neuronal spinal cord activity (Millan, 2002),
thereby weakening or potentiating descending pain transmission.
Therefore, the role of 5-HT in analgesia remains controversial.
The effect of selectively inhibiting 5-HT reuptake has mainly
been studied using SSRIs like fluoxetine. The anti-nociceptive
effect of fluoxetine has been demonstrated in several animal
models of acute and chronic pain (tail flick, hot plate and
streptozotocin diabetic mice), although the data obtained have
at times been contradictory (Singh et al., 2001; Cervantes-Durán
et al., 2013). Thus, 5-HT has a pro-nociceptive peripheral effect,
as reflected by the enhanced pain in the formalin test after local
fluoxetine injection. However, systemic and intrathecal injection
reduces any pro-nociceptive behavior in this test (Cervantes-
Durán et al., 2013). The peripheral pro-nociceptive effect seems
to be mediated by the activation of 5-HT2A/2B/2C/3/4/6/7
receptors, while systemic and intrathecal anti-nociception seems
to be mediated by 5-HT1A/1B/1D/5A receptor activation.
The pro-nociceptive effect of 5-HT on some 5-HT receptors
reveals the importance of co-administering certain 5-HT
antagonists in pain management. As such, analgesia is enhanced
when 5-HT1A receptors are blocked with drugs that augment
5-HT. Accordingly, the anti-nociceptive effect of the SNRI
venlafaxine (injected subcutaneously) was potentiated in the hot
plate test by 5-HT1A receptors antagonism. Similarly, systemic
co-administration of a 5-HT1A receptor antagonist enhanced
fluoxetine-induced anti-nociception in the acetic acid test (Singh
et al., 2001). Moreover, several studies showed that systemic
blockage of 5-HT1A receptors enhances the analgesic effect
of SSRIs like fluoxetine (Anjaneyulu and Chopra, 2004) and
clomipramine (Ardid et al., 2001) in chronic pain models. In
fact, chronic intracerebroventricular (ICV) administration of an
antisense oligodeoxynucleotide that silences 5-HT1A receptor
synthesis decreases mechanical hypersensitivity of neuropathic
rats (Hernandez et al., 2004). These results provide strong
evidence of the importance of co-administering selective 5-
HT1A antagonists to potentiate the anti-nociceptive efficacy
of antidepressants.
The antagonism of 5-HT2 receptors potentiates the anti-
nociceptive effect of paroxetine, effect that is blocked by 5-HT3
antagonist in the acetic acid test (Kesim et al., 2005). However,
ketanserin (a 5-HT2A/AC receptor antagonist) antagonizes
the anti-allodynic effect of fluvoxamine in a mice model of
neuropathic pain. These findings suggest that SSRIs would have
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an opposite effect on 5-HT2A/2C receptors in acute or chronic
pain (Honda et al., 2006).
There is little information about the role of 5-HT receptors
in chronic pain and despite the influence of 5-HT on pain
modulation, some preclinical studies have reported that the
analgesia produced by SSRIs is less potent in chronic than in
acute pain models (Bardin et al., 2000; Pichon et al., 2010). In
fact, the stimulation of 5-HT2A receptors induces analgesia in
healthy but not diabetic neuropathic rats. Thus, the alterations to
5-HT2A receptors that occurs in neuropathic pain is thought to
be one of the causes of this inefficacy. In fact, pharmacological
disruption of the association between spinal serotonin type
2A (5-HT2A) receptors and their associated PDZ proteins
suppresses the analgesia induced by fluoxetine in diabetic and
SNL rats (Pichon et al., 2010). Hence, 5-HT2A receptors and
PDZ protein interactions might influence the resistance to SSRI-
induced analgesia in the management of chronic neuropathic
pain. Coupling the pro-nociceptive stimulation of some 5-HT
receptors to the 5-HT alterations observed in chronic pain
possibly explains the inefficacy of SSRIs in the management
of chronic pain.
Clinical Approach
Although modulation of the 5-HT system could dampen or
enhance the magnitude of pain, antidepressants like SSRIs that
selectively acting through 5-HT are thought to be relatively poor
in combating chronic pain (Johansson and Von Knorring, 1979;
Anderberg et al., 2000) and therefore, they are not recommended
as a first-line therapy for chronic pain. Fluoxetine and paroxetine
have been used unsuccessfully to manage non-neuropathic
chronic pain like headache and migraine (Saper et al., 1994,
1995), and paroxetine and citalopram have minimal effects
on patients suffering painful diabetic neuropathy. Similarly,
fluoxetine had no effect in patients with painful diabetic
neuropathy (Sindrup et al., 1990, 1992; Max et al., 1992). Animal
studies have helped us to elucidate some possible mechanisms
responsible for the ineffectiveness of SSRIs in chronic pain, such
as the facilitatory role of serotonin on 5-HT3 receptors and the
alterations to 5-HT2A receptors in this condition. However, other
drugs with dual action on NA and 5-HT reuptake inhibitors have
proved to be efficacious in treating several forms of chronic pain,
such as venlafaxine and duloxetine for fibromyalgia, migraine
and diabetic neuropathy (Kaur et al., 2011; King et al., 2015;
Burch, 2019). Hence, further studies should be carried out to
assess how to achieve effective analgesia through the 5-HT
system. By contrast, there is no evidence to support the use
of SSRIs to combat inflammatory chronic pain like rheumatoid
arthritis or osteoarthritis (Perrot et al., 2008).
Action on the Dopaminergic System
Preclinical Studies
The descending release of DA in the spinal cord plays an
important role in pain modulation, although there are limited
studies into the dopaminergic influence on the analgesic effect
of antidepressants. Intrathecal injection of bupropion produces
a dose-dependent anti-hyperalgesic effect in neuropathic rats,
coincident with an increase in NA and DA in the spinal
cord (Hoshino et al., 2015). In addition, the norepinephrine-
dopamine reuptake inhibitor nomifensine has a similar potency
and efficacy to morphine in the formalin test (Gilbert and
Franklin, 2001). It was recently reported that spinal DA
receptors are implicated in the anti-hyperalgesic effect of
antidepressants in a model of spinal nerve ligation. Pretreatment
with a dopamine D2 receptor antagonist abolished the anti-
hyperalgesic effects of intraperitoneal amitriptyline, duloxetine,
milnacipran and fluoxetine administration (Chen et al., 2017),
suggesting that DA would exert a role in the spinal inhibitory
effect of antidepressants. Nevertheless, further studies into the
implication of the DA system in pain should be carried out.
Clinical Approach
Few studies have evaluated the analgesic effectiveness of specific
DA reuptake inhibition in chronic pain patients. In this regard,
the atypical antidepressant bupropion (a dual noradrenaline and
dopamine reuptake inhibitor) decreases the intensity of pain
and improves the quality of life of neuropathic pain patients
(Semenchuk and Davis, 2000). However, the side effects of
this drug are an important drawback as bupropion may be an
excessively strong stimulant, inhibiting the appetite. As such, it
is absolutely contraindicated in patients with a history of seizures
or eating disorders.
Nonetheless, new TRIs have been designed that block all
three monoamines by acting on their transporters (DAT, NAT
and SERT: dopamine, noradrenaline, and serotonin transporters:
Hache et al., 2011). These drugs should theoretically be very
efficacious in treating chronic pain and they could be useful when
pain is co-morbid with other conditions in which the availability
of some monoamines is compromised, such as in depression or
Parkinson’s disease. However, whether these drugs truly represent
an interesting new strategy remains to be fully explored.
Gabapentinoids
Preclinical Studies
Gabapentin was introduced as an antiepileptic drug in 1993 and
it was subsequently recognized as a first-line drug for several
types of chronic pain. Gabapentinoids have been widely used
to treat neuropathic pain and they are mainly characterized
by their action on α2δ subunits in primary afferents. However,
they may also act on supraspinal areas and stimulate descending
pain inhibition, with their supraspinal effects mediated by
spinal α2-ARs (Table 3; Takasu et al., 2006). Accordingly,
high doses of gabapentin and pregabalin (ICV), and i.v.
administration of gabapentin, enhances NA turnover in the
spinal cord (Takeuchi et al., 2007; Hayashida et al., 2008; Tanabe
et al., 2008), provoking spinal α2-AR mediated analgesia. In
murine models of neuropathic pain, α2 antagonists suppress
the anti-hypersensitivity effect of gabapentinoids following ICV
administration (Tanabe et al., 2008). There have been few studies
into gabapentinoids and the serotonergic system, yet the increase
in 5-HT3 receptors after injury determines the analgesic actions
of gabapentinoids (Bee and Dickenson, 2008). Conversely,
pregabalin induced pain relief via the intra-accumbens nucleus
induces DA release during early but not late neuropathic
pain (Kato et al., 2016). Hence, pain chronification leads to





















TABLE 3 | Analgesic action of gabapentinoids, opioids, NSAID’s and histaminergic drugs via monoaminergic system.
Drugs Effective Dose Model of pain Nociceptive
test
Effect Receptors Effect antagonized by Animal References
Gabapentinoids
Gabapentin 100 µg i.c.v. Neuropathic:
PSL
Plantar test ↑ Latency α2-AR Yohimbine (3 µg, i.t.) Mice Takasu et al., 2006
von Frey test ↑ Latency Idazoxan (3 µg, i.t.)
Gabapentin 1 µg intra LC Neuropathic:
SNL
Randall-Selitto ↑ Latency α2-AR Idazoxan (30 µg, i.t.) Rat Hayashida et al., 2008
Gabapentin 100 µg i.c.v. Neuropathic:
PSL
Plantar test ↑ Latency α2-AR Idazoxan (3 µg, i.t.) Mice Takeuchi et al., 2007
Pregabalin 30 i.c.v. von Frey test ↑ Latency α2-AR
Gabapentin 100 mg/kg i.p. Neuropathic:
PSL
Plantar test ↑ Latency α2-AR Yohimbine (1 mg/kg i.p.; 3 µg i.t) Mice Tanabe et al., 2008
100 µg i.t. von Frey test ↑ Latency
Opioids
Beta-endorphin 1 nmol / 10 µl i.t. Heat
stimulation
Tail-flick test ↑ Latency 5-HT1 Spiroxatrine (15 µg/10 µl) Rat Crisp et al., 1989
5-HT3 ICS 205-930 (15 µg/10 µl)
5-HT2 Ritanserin (15 µg/10 µl)
α2-AR Yohimbine (15 µg/10 µl)




α2-AR Yohimbine (5, 10, 20 mg/paw) Rat Romero et al., 2012
SCN 80 20 µg/paw α2A-AR BRL 44480 (20 µg/paw)
Bremazocine 20 µg/paw α2B-AR Imiloxan (20 µg/paw)
α2C-AR RAU (10, 15, and 20 µg/paw)
α2D-AR RX 821002 (20 µg/paw)
α1-AR Prazosin (0.5, 1, 2 µg/paw)
β-AR Propanolol (150, 300, 600 ng/paw)
Morphine 7.5 nmol/10 µl i.t Heat
stimulation
Tail-flick test ↑ Latency 5-HT2 Ketanserin (50 nmol, i.t.) Rat Kellstein et al., 1988
Methysergide (20 nmol i.t.)




Acetic acid test ↓ Writhes 5-HT1A Naloxone (5 mg/kg i.p.) Mice Singh et al., 2001
Naltrexone (5 mg/kg i.p.)
NSAID’s
Paracetamol 400 mg/kg i.p. Hot plate test ↑ Reaction time 5-HT2 [3H]Ketanserin binding Rat Pini et al., 1996


















































TABLE 3 | Continued
Drugs Effective Dose Model of pain Nociceptive
test
Effect Receptors Effect antagonized by Animal References
Dypirone 20 µg/paw PGE2
(intraplantar)
Randall-Selitto ↑ Latency α2-AR Yohimbine (2.5, 5, 10, 20 mg/paw) Rat Silva et al., 2015
Diclofenac 40 µg/paw α2C-AR RAU (10, 15, 20 µg/paw)
α1-AR Prazosin (0.5, 1, 2 µg/paw)
β-AR Propanolol (0.3, 0.6, 1.2 µg/paw)
Histamines
Chlorpheniramine 15 mg/kg i.p. Neuropathic:
TNT
von Frey test ↑ Latency H1 Rat Khalilzadeh et al., 2018
Ranitidine 15 mg/kg i.p. Acetone test ↑ Latency H2
Histidine 100 mg/kg, i.p. Neuropathic:
PSL
von Frey test ↑ Latency H1 Mepyramine (200 ng/rat i.t. or i.c.v) Rat Yu et al., 2016
Plantar test ↑ Latency





Pinprick test ↑ Latency H1 Rat Jaggi et al., 2017
Ranitidine 20, 20 mg/kg, i.p.
(12 days)
Acetone test ↑ Latency H2
Hot plate test ↑ Latency




von Frey test ↑ Latency H3 Pyrilamine (H1 receptor antagonist,
10 µg i.t.)
Mice Popiolek-Barczyk et al.,
2018
TR-7 Cold plate ↑ Latency H4
Tail-flick test ↑ Latency




Randall-Selitto ↑ Latency H3 Rat Chaumette et al., 2018













Plantar test ↑ Latency H4 Rat Hsieh et al., 2010
Inflammatory




Plantar test ↑ Latency H4 JNJ 10191584 (6 mg/kg p.o.) Mice Sanna et al., 2015, 2017
VUF8430 20 and 40 µg
i.c.v.
Von Frey test ↑ Latency
AR, adrenoceptor; ASA, Acetylsalicylic acid; CCI, chronic constriction injury; i.c.v, intracerebroventricular injection; i.p., intraperitoneal injection; i.t. intrathecal injection; p.o, oral administration; PSL, partial ligation of the




















fnins-13-01268 November 22, 2019 Time: 16:28 # 15
Bravo et al. Monoamines as Target in Chronic Pain
dysfunction of the reward circuit, which should be studied as a
target for the management of chronic pain.
Clinical Approach
Gabapentinoids are mainly effective in the treatment of chronic
neuropathic pain, with gabapentin and pregabalin the drugs
considered to most effectively relieve neuropathic pain (e.g.,
diabetic neuropathy and post-herpetic neuralgia). However, in
terms of non-neuropathic pain only pregabalin has been seen
to be efficacious in the treatment of fibromyalgia (Wiffen
et al., 2013). Most clinical trials indicate that antidepressants
and gabapentinoids produce comparable analgesia, mainly in
neuropathic pain patients, yet more recent trials attempted to
see if analgesia is improved by combining these two drugs.
For neuropathic pain (diabetic neuropathy or post-herpetic
neuralgia), the combined action of gabapentin and the TCA
nortriptyline proved to be more efficacious than either drug
alone (Gilron et al., 2009). The combination of pregabalin and
duloxetine was well tolerated in diabetic neuropathy patients,
although it did not produce better analgesia than either drug
alone (Tesfaye et al., 2013). Interestingly, this combination
produced a notably better clinical outcome in fibromyalgia when
compared to monotherapy (Gilron et al., 2016). There is little
data regarding the use of gabapentinoids in pain with a pure
inflammatory component, although a recent study indicated
that the combination of pregabalin with a NSAID in knee
osteoarthritis patients with neuropathic pain was more effective
than monotherapy with the NSAID alone (Filatova et al., 2017).
The Combination of Monoamines and
Opioids
Preclinical Studies
Opioids are first line treatments for many types of chronic pain
and several studies have reported combined effects between the
opioid and monoaminergic systems (Table 3; Schroder et al.,
2011; Bravo et al., 2017). Opioid receptor agonists induce NA
release at supraspinal, spinal and peripheral sites (Wigdor and
Wilcox, 1987; Grabow et al., 1999) where they would exert
analgesic actions. Early studies reported that α2-ARs mediate
analgesia of β-endorphin at the spinal cord (Crisp et al.,
1989) and that naloxone antagonizes intrathecal NA-induced
anti-nociception, suggesting that opioids are involved in NA
spinal analgesia. Interestingly, co-administration of TCAs and
morphine enhance analgesia in mice (Kellstein et al., 1984;
Hwang and Wilcox, 1987; Gray et al., 1999; Reimann et al., 1999),
and α2-ARs are thought to be responsible for this synergistic
action (Stone et al., 1999). Recent studies demonstrated that
opioids and cannabinoids induce peripheral anti-nociception
by releasing NA, which activates the α2-, α1- and β-ARs
(Romero et al., 2012).
However, there are is some controversy as to whether opioids
mediate spinal anti-nociception via NA or 5-HT. Inhibition
of both NA and 5-HT reuptake appears to induce analgesic
synergy with morphine in the formalin test, although excess 5-
HT may stimulate 5-HT3 receptors and reduces this synergy
(Shen et al., 2013). Alternatively, there is evidence that opioids
mediate spinal 5-HT anti-nociception (Kellstein et al., 1988;
Kishimoto et al., 2001) and moreover, the anti-nociceptive effect
of fluoxetine in the acetic acid test is sensitive to blockade
by naloxone (Singh et al., 2001), suggesting a clear opioid
component in this effect.
Clinical Approach
Combining monoamines and opioids enhances analgesia in
animal models, although in only one clinical trial were benefits
reported using the combination of nortriptyline and morphine
(Gilron et al., 2015). Unfortunately, this combination induces
the classic adverse effects of opioids (constipation, dry mouth
and somnolence) and could compromise patient safety. Hence,
drugs are being designed that offer a reasonable safety profile
and that combine monoaminergic and opioid actions. This is the
case of tramadol, a mu-opioid agonist and SNRI, and tapentadol,
a potent mu-opioid agonist and NA reuptake inhibitor. These
drugs relieve certain types of chronic pain but they do not
appear to have a reliable effect on neuropathies (Silverfield et al.,
2002; Duehmke et al., 2017), which has led to them being more
commonly recommend as second-line therapy.
NSAIDs
Preclinical Studies
Preclinical and clinical studies demonstrated the efficacy of
NSAIDs, mainly in chronic inflammatory pain (Cohen and
Harris, 1987; Vo et al., 2009), and they are commonly prescribed
for acute and persistent inflammatory pain. The peripheral
inhibition of prostaglandins is not the only analgesic mechanism
of action, given its central action on the noradrenergic and
serotonergic system (Table 3). Acetyl salicylic acid (ASA) induced
analgesia is accompanied by an increase in the turnover of 5-
HT, NA and DA (Bensemana and Gascon, 1978), and a potent
relationship has been described between 5-HT and NSAIDs.
Acute administration of phenazone decreases 5-HT binding,
whereas chronic treatment provokes an increase in 5-HT binding
sites in the pontine and cortical areas, induced by an increase in
5-HT (Sandrini et al., 1998). The anti-nociceptive effect of ASA
was impeded by i.p. pre-treatment with a 5-HT neurotoxin in
the hot plate test (Pini et al., 1996). Moreover, ASA potentiated
the anti-nociceptive effect of morphine in the second phase of the
formalin test, accompanied by an increase in extracellular 5-HT
and a decrease in 5-HT2 receptors in the cortex (Sandrini et al.,
1998). Similar findings were reported with the combination of
paracetamol and morphine. More recently, adrenergic receptors
have been implicated in the anti-nociceptive effect of NSAIDs.
Thus, intrathecal ketorolac enhances the effect of clonidine
against a noxious heat stimulus in rats, yet it lacks efficacy when
administered alone (Conklin and Eisenach, 2003). Additionally,
the peripheral depletion of NA prevented the anti-nociceptive
effect of dipyrone and diclofenac in a model of inflammatory
pain, while prazosin (an α1 antagonist) and propranolol (a
β-adrenergic antagonist) blocked the anti-nociceptive effect of
dipyrone and diclofenac (Silva et al., 2015), suggesting that
NSAID analgesia is mediated by adrenergic receptors. There
are no relevant studies into the analgesic efficacy of NSAIDs
in animal models of neuropathic pain (Lashbrook et al., 1999),
yet further preclinical studies into both chronic neuropathic
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and inflammatory pain should elucidate the possible interaction
between NSAIDs and monoamines.
Clinical Approach
NSAIDs are routinely prescribed for the management of chronic
inflammatory pain since their main mechanism of action
involves the peripheral inhibition of inflammatory mediators
(prostaglandins), provoking weaker peripheral sensitization.
However, the oral NSAIDs used have more severe adverse
effects when administered chronically (peptic ulcer disease,
acute renal failure and stroke/myocardial infarction) and thus,
topical rather than oral administration is recommended. In
clinical practice, NSAIDs have relevant peripheral activity but
recently, there is recent evidence that they may facilitate
activation of the descending inhibitory circuitry at the level of
the spinal cord and brain (Hodkinson et al., 2015). In terms
of neuropathic pain, NSAIDs have no effect and there is only
modest evidence of efficacy in patients with chronic low back pain
(Enthoven et al., 2017).
Histaminergic Drugs
Recent, preclinical findings support the use of ligands
of histamine receptors as analgesics in neuropathic and
inflammatory pain (Table 3; Obara et al., 2019). For example,
the systemic administration of H1 and H2 receptor antagonists
(like chlorpheniramine and ranitidine, respectively) produces
anti-allodynic effects in a model of neuropathic pain in rats
(Khalilzadeh et al., 2018). Interestingly, several studies suggest
that H1 but not H2 receptors are involved in the development
of hypersensitivity following partial ligation of the sciatic
nerve and in vincristine-induced models of neuropathic pain
(Yu et al., 2016; Jaggi et al., 2017).
Although most studies suggest that the systemic use of
histamine H3 receptor antagonists produces inhibitory effects
on nociceptive responses in neuropathic pain (Farzin and
Nosrati, 2007; Chaumette et al., 2018; Popiolek-Barczyk et al.,
2018), there is evidence that activation of H3 receptors has
inhibitory effects on pain (Cannon et al., 2003). Interestingly,
chronic oral administration of S38093 or A-960656, selective
H3 receptor antagonist/inverse agonists, increased the paw
withdrawal threshold to mechanical stimuli in neuropathic and
inflammatory pain models, showing similar effects to gabapentin
and/or pregabalin (Cowart et al., 2012; Chaumette et al., 2018).
Moreover, the analgesic effect of S38093 is thought to be
partially mediated by a2-AR desensitization in the LC, suggesting
that the noradrenergic system is crucial for H3 antagonists
to produce antinociception (Chaumette et al., 2018). In fact,
bilateral lesions of the LC and spinal cord transection completely
inhibited the effects of H3 antagonist, on spontaneous and evoked
firing of spinal neurons in neuropathic rats (McGaraughty
et al., 2012). Like H3 receptors, H4 receptor agonists and
antagonists have different effects on the nociceptive response.
Thus, systemic administration of JNJ 7777120, a histamine
H4 receptor antagonist, reduced mechanical hypersensitivity in
chronic constriction injury (CCI) and SNL neuropathic models
(Hsieh et al., 2010). In addition, single doses of the selective H4
receptor antagonist TR-7 elicit a strong analgesic effect (Popiolek-
Barczyk et al., 2018). By contrast, local ICV administration of the
H4 receptor agonists ST-1006 and VUF8430, reduced nociceptive
thresholds in mice with neuropathic pain (Sanna et al., 2015).
Overall, there appears to be a clear effect of histamine in
chronic pain that depends on multiple factors, such as the
localization of the receptors, or the affinity and selectivity of
ligands for histamine receptors (Obara et al., 2019). Thus, a better
understanding of the histaminergic system in pain modulation
will help us to identify histaminergic targets that could lead to
more efficient pharmacological therapy for neuropathic pain.
DISCUSSION
The monoaminergic system is important in both the healthy
state and in pain modulation, the correct balance between
the excitatory and inhibitory inputs on descending pain
pathways producing analgesia. However, when biological pain
shifts to pathological pain, the monoaminergic system suffers
alterations that would contribute to the sensitization and
maintenance of pain. To search for pharmacological new
targets, the monoaminergic mechanisms underlying chronic
pain are of great interest. In fact, chronic pain, and explicitly
neuropathic pain, is treated with medications that affect
monoamines. Antidepressants are drugs that effect monoamines
directly, although they were designed to treat depression
and they are currently used as first line treatments for
neuropathic pain due to their intrinsic analgesic action. In
recent decades, antidepressants have been seen to have greater
clinical efficacy in neuropathic pain than in inflammatory
pain (Finnerup et al., 2005; Sindrup et al., 2005). From an
etiological point of view, neuropathic pain is due to lesion
or dysfunction in the PNS/CNS that causes monoaminergic
dysfunction, yet inflammatory pain is caused by the action of
inflammatory mediators on nociceptors in the periphery and
subsequently, changes in the excitability of central neurons.
The analgesic mechanism of action of antidepressants is
thought to involve inhibition of both NA and 5-HT reuptake
at spinal and brain levels, and the subsequent modulation
of descending pain pathways. Thus, it is plausible that
antidepressants exert positive clinical outcomes in pain with a
neuropathic component.
In addition, antidepressants exhibit significant analgesia
in chronic pain, yet moderate efficacy against acute pain
(Poree et al., 1998; Sawynok et al., 2001; Paqueron et al.,
2003; Mico et al., 2006). As indicated, the increase of α2-
AR efficacy at the spinal level seems to promote better
analgesia of antidepressants (Stone et al., 1999; Bantel et al.,
2005). Moreover, supraspinal noradrenergic centers like the LC
are altered in chronic pain, alterations that are relevant for
the development of chronic pain-related co-morbidities like
anxiety and depression (Alba-Delgado et al., 2013, 2018), and
which are commonly treated with antidepressants. Although
antidepressants mainly act through the NA and 5-HT system,
the repercussion of each system on anti-nociception remains
unclear. Antidepressants that affect both noradrenaline and
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serotonin levels, like duloxetine and amitriptyline, are more
potent and efficient than SSRIs in relieving chronic pain
(Marchand et al., 2003; Finnerup et al., 2005). Considering data
from animal studies, milnacipran (a SNRI) but not paroxetine
(a SSRI) attenuates mechanical hypersensitivity in a model of
neuropathic pain (SNL: Bomholt et al., 2005). Furthermore,
the anti-nociceptive effect of drugs that act selectively on 5-
HT (e.g., SSRIs) is less potent in chronic than in acute pain
(Bardin et al., 2000; Pichon et al., 2010). This phenomenon
could be explained by the pro-nociceptive effect of spinal 5-HT
receptors in some states of chronic pain and by the alterations
to 5-HT2A receptors observed in neuropathic pain (Honda
et al., 2006; Pichon et al., 2010). These studies reveal the
importance of studying 5-HT receptor agonists/antagonists in
pain management. Currently, no drugs used to manage chronic
pain target 5-HT receptors, except the 5-HT1B/1D agonists
used to treat chronic migraine and headache. Interestingly,
drugs that mainly inhibit noradrenaline reuptake, like DMI
and maprotiline, are not a good choice for pain relief,
as reflected by their moderate relief in the treatment of
human neuropathic pain (Max et al., 1991, 1992; Vrethem
et al., 1997), revealing the importance of increasing both
extracellular NA and 5-HT.
Clinical evidence suggests TCAs are more efficacious in several
chronic pain conditions. In particular, amytriptiline is considered
the gold standard to manage neuropathic pain irrespective
of its etiology (Saarto and Wiffen, 2007), although the main
drawback of these drugs are their adverse effects. However,
optimum analgesia is usually achieved at lower doses than those
required for their antidepressant activity and thus, such side
effects occur less frequently. Non-tricyclic antidepressants are
thought to be safer than TCAs, and duloxetine is the first
antidepressant approved by the FDA to treat neuropathic pain,
considered the best election for peripheral diabetic neuropathic
pain (Kaur et al., 2011; King et al., 2015). Less convincing
results have been obtained in terms of the selective action on
5-HT receptors, yet preclinical studies indicate that the co-
administration of antidepressants with certain 5-HT receptor
antagonists (e.g., those of the 5-HT1A receptor) potentiates
the analgesic effect of these drugs (Ardid et al., 2001; Singh
et al., 2001; Anjaneyulu and Chopra, 2004). Recently, other
atypical antidepressants like melatonin and agomelatonine
have been shown to have promising analgesic effects to treat
neuropathic pain, acting via MT1/MT2 melatonin receptors
and the monoaminergic system (Ambriz-Tututi et al., 2009;
Lopez-Canul et al., 2015; Chenaf et al., 2017). Moreover, the
introduction of TRIs represents a new strategy that can be
explored in the management of chronic pain. As indicated,
chronic pain induces important changes in the NA, 5-HT and DA
system, and as such, these drugs would maintain optimal levels of
these neurotransmitters that allow a longer interaction with the
appropriate receptors.
In addition to antidepressants, other drugs that directly
and indirectly effect the monoaminergic system are also used
to treat chronic pain. Thus, atypical opioids that combine
monoaminergic and opioid effects are more efficacious than
other opioids in neuropathic pain models (Christoph et al., 2007;
Meske et al., 2014). In fact, tramadol tapentadol are situated
on the second third step of the WHO analgesic scale (WHO,
Bravo et al., 2017). Conversely, gabapentinoids mediate analgesia
via spinal α2-ARs (Takasu et al., 2006) and they have been
approved by the FDA to treat neuropathic pain (Goodman and
Brett, 2019). The efficacy of gabapentinoids is comparable to
that of antidepressant drugs in clinical trials, yet they differ
in safety and tolerability (Morello et al., 1999; Sindrup and
Jensen, 2000). They now represent an alternative for neuropathic
pain patients for whom amytriptiline is contraindicated. Finally,
NSAIDs are drugs that act on the monoaminergic system,
yet with limited information regarding their mechanism of
action. In general, NSAIDs seem to potentiate the analgesic
effect of drugs like morphine and tramadol, and recently, their
activity was associated with α1- and β-ARs (Silva et al., 2015).
Clinically, there is a little evidence of the potency and efficacy
of NSAIDs in chronic pain, or of their use in combination with
other drugs (Ong et al., 2007). Finally, although there are no
histaminergic drugs that relieve chronic pain, preclinical studies
indicate that it is time to reconsider the histamine system as
a therapeutic target for the management of inflammatory and
neuropathic pain.
In conclusion, an extracellular increase in NA and
5-HT significantly helps relieve chronic pain. Indeed,
chronic neuropathic pain is commonly treated with TCA
and SNRI antidepressants, and by gabapentinoid drugs
when antidepressants are contraindicated. Given that
the monoaminergic system is closely linked to disorders
like depression and anxiety, clinical situations frequently
associated with chronic pain, the monoaminergic system
is a pharmacological target that could help treat the
sensory and emotional aspects of chronic pain. However,
despite the promising preclinical and clinical results
obtained, complete relief from chronic pain via the
monoaminergic system remains a challenge. Thus, there
is a need for further preclinical and clinical studies to
further assess the selective targeting of the monoaminergic
system to achieve successful analgesia for the treatment of
chronic pain.
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